[go: up one dir, main page]

ES2036558T3 - Metodo para preparar composiciones farmaceuticas de interleucina-2 recombinante. - Google Patents

Metodo para preparar composiciones farmaceuticas de interleucina-2 recombinante.

Info

Publication number
ES2036558T3
ES2036558T3 ES198787115694T ES87115694T ES2036558T3 ES 2036558 T3 ES2036558 T3 ES 2036558T3 ES 198787115694 T ES198787115694 T ES 198787115694T ES 87115694 T ES87115694 T ES 87115694T ES 2036558 T3 ES2036558 T3 ES 2036558T3
Authority
ES
Spain
Prior art keywords
pharmaceutical compositions
interleukin
preparing recombinant
recombinant pharmaceutical
solubilizer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787115694T
Other languages
English (en)
Inventor
Ze'ev Shaked
Tracy Stewart
James William Thomson
Pamela Hirtzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Application granted granted Critical
Publication of ES2036558T3 publication Critical patent/ES2036558T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE PREPARAN COMPOSICIONES FARMACEUTICAS ADECUADAS PARA ADMINISTRACION PARENTERAL A ANIMALES O HOMBRES, QUE COMPRENDEN UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE UNA PROTEINA INTERLEUCINA-2 RECOMBINANTE (1L-2) DISUELTA EN UN VEHICULO INERTE QUE COMPRENDE UNO O MAS DETERGENTES NO-IONICOS POLIMERICOS QUE ACTUAN COMO SOLUBILIZANTESESTABILIZANTES DE LAS FORMULACIONES REIVINDICADAS.
ES198787115694T 1986-10-27 1987-10-26 Metodo para preparar composiciones farmaceuticas de interleucina-2 recombinante. Expired - Lifetime ES2036558T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92338386A 1986-10-27 1986-10-27

Publications (1)

Publication Number Publication Date
ES2036558T3 true ES2036558T3 (es) 1993-06-01

Family

ID=25448603

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787115694T Expired - Lifetime ES2036558T3 (es) 1986-10-27 1987-10-26 Metodo para preparar composiciones farmaceuticas de interleucina-2 recombinante.

Country Status (9)

Country Link
EP (1) EP0268110B1 (es)
JP (1) JPS63122628A (es)
AT (1) ATE74512T1 (es)
AU (1) AU614066B2 (es)
CA (1) CA1292686C (es)
DE (1) DE3778122D1 (es)
ES (1) ES2036558T3 (es)
GR (1) GR3004479T3 (es)
IE (1) IE60890B1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US6060459A (en) * 1987-10-28 2000-05-09 Pro-Neuron, Inc. Enhancing blood cell count with oxypurine nucleosides
ES2054099T3 (es) * 1988-12-06 1994-08-01 Otsuka Pharma Co Ltd Composicion estabilizada de interleucina-1-g(b).
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
JPH0791318B2 (ja) * 1989-09-21 1995-10-04 三井東圧化学株式会社 蛋白質水溶液、蛋白質水溶液の濃度増大方法および蛋白質製剤
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
US20030171292A1 (en) 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
KR100303872B1 (ko) * 1992-10-02 2001-11-22 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법
AU687763B2 (en) * 1992-10-20 1998-03-05 Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service Interleukin-6 receptor antagonists
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
PL372138A1 (en) 2001-10-15 2005-07-11 Chiron Corporation Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
EP2149585B1 (en) 2003-11-04 2013-08-14 Novartis Vaccines and Diagnostics, Inc. Use of antagonistic anti-CD40 monoclonal antibodies
ATE474599T1 (de) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40- monoklonalen antikörpern zur behandlung von multiplem myelom
EP2243491A1 (en) 2003-11-04 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-CD40 monoclonal antibodies for treatment of chronic lymphocytic leukemia
ATE476991T1 (de) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verfahren zur behandlung von soliden tumoren mit expression des cd40-zelloberflächen-antigens
EP1844815B1 (en) 2003-11-04 2011-09-14 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
GB0404586D0 (en) * 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
KR100624013B1 (ko) 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
JP5518608B2 (ja) * 2010-07-09 2014-06-11 ロート製薬株式会社 粘膜適用液状組成物
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
NZ611176A (en) 2010-12-02 2015-07-31 Bionor Immuno As Peptide scaffold design
CA2821995C (en) 2011-01-06 2019-02-12 Bionor Immuno As Monomeric and multimeric peptides immunogenic against hiv
DE102012101864A1 (de) * 2012-03-06 2013-09-12 Gramme-Revit Gmbh Mittel zur Behandlung von Allergien und anderen Erkrankungen
CA2874923C (en) 2012-06-06 2021-08-31 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
UA105278C2 (ru) 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
IL291122B2 (en) 2013-04-23 2024-01-01 Cedars Sinai Medical Center Methods and systems for simultaneous recording of a visible light image and an infrared light image FLUOROPHORES
RU2682335C2 (ru) 2014-01-17 2019-03-19 Сидарс-Синай Медикал Сентр Рецептор-направленные конструкции и их применение
CA2937035A1 (en) 2014-02-05 2015-08-13 Cedars-Sinai Medical Center Methods and compositions for treating cancer and infectious diseases
KR102567244B1 (ko) 2014-06-12 2023-08-16 세다르스-신나이 메디칼 센터 암을 치료하는 조성물 및 방법
CN115607688A (zh) 2014-07-22 2023-01-17 雷莫内克斯生物制药有限公司 用于递送生物活性物质或蛋白质的组合物及其用途
CN107106669A (zh) 2014-11-04 2017-08-29 南加利福尼亚大学 用于治疗过度表达HIF‑1α的癌症的组合物和方法
EP3800199B1 (en) 2015-05-05 2024-08-21 The Regents of The University of California H3.3 ctl peptides and uses thereof
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US11567078B2 (en) 2015-08-31 2023-01-31 Cedars-Sinai Medical Center Blood cell biomarker for late onset Alzheimer's disease
WO2017138924A1 (en) 2016-02-09 2017-08-17 Autotelic Llc Compositions and methods for treating pancreatic cancer
WO2017138925A1 (en) 2016-02-09 2017-08-17 Autotelic Llc Antitumour combinations of antisense oligonucleotides and anticancer agents
EP3468546A4 (en) 2016-06-09 2020-04-01 Cedars-Sinai Medical Center COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
EP3578171A4 (en) 2017-02-06 2020-12-30 Lemonex Inc. PHYSIOLOGICALLY ACTIVE SUBSTANCE CARRIER
WO2018143787A1 (ko) 2017-02-06 2018-08-09 주식회사 레모넥스 생리활성물질 전달체
EP3658139A4 (en) 2017-07-25 2021-04-07 Cedars-Sinai Medical Center Methods for treating liver diseases
WO2019040647A1 (en) 2017-08-22 2019-02-28 Cedars-Sinai Medical Center COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
KR102152348B1 (ko) 2017-09-05 2020-09-08 주식회사 레모넥스 세포 운명 조절용 조성물
KR102753455B1 (ko) 2018-08-08 2025-01-10 세다르스-신나이 메디칼 센터 암 및 자가면역 질환을 치료하기 위한 조성물 및 방법
CA3117386A1 (en) 2018-11-08 2020-05-14 Cedars-Sinai Medical Center Use of clazakizumab to desensitize and improve renal transplantation in hla-sensitized patients
JP2022514381A (ja) 2018-12-20 2022-02-10 セダーズ－シナイ メディカル センター 臓器移植の慢性抗体介在性拒絶反応の処置でのクラザキズマブ
BR112022011513A2 (pt) * 2019-12-13 2022-08-23 Synthekine Inc Ortólogos de il-2 e métodos de uso
JP7757797B2 (ja) * 2020-01-28 2025-10-22 日本ゼオン株式会社 プレフィルド薬剤パッケージ及びプレフィルド薬剤パッケージの製造方法
WO2021160887A1 (en) 2020-02-14 2021-08-19 Immunor As Corona virus vaccine
CA3172871A1 (en) * 2020-05-11 2021-11-18 Francisca O. GBORMITTAH Il-2 fusion polypeptide compositions and methods of making and using the same
KR20230107598A (ko) * 2020-11-13 2023-07-17 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 인간 인터루킨 2 변이체 또는 이의 유도체를 포함하는 약학적 조성물 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
DE3575072D1 (de) * 1984-03-28 1990-02-08 Cetus Corp Pharmazeutische zusammensetzungen von mikrobenerzeugtem interleukin-2.
DE3583880D1 (de) * 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
CA1297003C (en) * 1985-09-20 1992-03-10 Jack H. Nunberg Composition and method for treating animals
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like

Also Published As

Publication number Publication date
AU614066B2 (en) 1991-08-22
IE872844L (en) 1988-04-27
EP0268110B1 (en) 1992-04-08
JPS63122628A (ja) 1988-05-26
AU8018187A (en) 1988-04-28
ATE74512T1 (de) 1992-04-15
DE3778122D1 (de) 1992-05-14
EP0268110A1 (en) 1988-05-25
IE60890B1 (en) 1994-08-24
CA1292686C (en) 1991-12-03
GR3004479T3 (es) 1993-03-31

Similar Documents

Publication Publication Date Title
ES2036558T3 (es) Metodo para preparar composiciones farmaceuticas de interleucina-2 recombinante.
FI874706A0 (fi) Menetelmä glykosyloimattoman yhdistelmäinterferoni- :n stabiilien, farmaseuttisten koostumusten valmistamiseksi
DK0388220T3 (da) Præparater til vedvarende frigivelse af klorhexidin
AU590896B2 (en) Improved formulations for recombinant beta-interferon
NL930119I2 (nl) Farmaceutische en veterinaire preparaten van cysteine-125-verminderde muteïnen van interleukine-2 ende produktie daarvan.
ATE66817T1 (de) Stabile formulierung biologisch aktiver proteine zur parenteralen injektion.
DK0414263T3 (da) Fremgangsmåde til stabilisering af et fast farmaceutisk præparat indeholdende cycliske aminosyrer
ATE545430T1 (de) Hsa-freie interferon-beta formulierungen
FR2680507B1 (fr) Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP0321968A3 (en) Compounds active on the cardiovascular system
IT8323058A0 (it) Derivati di 2,5-piperazindione biologicamente attivi, processi per la loro preparazione e composizioni farmaceutiche che licontengono.
FR2707638B1 (fr) Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique.
DK78487A (da) Farmaceutisk praeparat indeholdende et i vand kvaeldende polymermateriale
SE8306225L (sv) 2-piperazinyl-kinazolinderivat, deras framstellning och farmaceutiska kompositioner innehallande desamma
FI870994A0 (fi) Foerfarande foer framstaellning av stabila, injekterbara farmaceutiska kompositioner, vilka innehaoller 1,4-dihydroxi-5,8-bis/2-(2-hydroxietylamino)etylamino/ antrakinondihydroklorid.
ES2126580T3 (es) Proteina condromodulina-ii.
FR2605223B1 (fr) Compositions therapeutiques stables a base d' huile vegetale hydrophobe et son procede de preparation
DE3781017D1 (de) Cytotoxische zusammensetzung aus "killer"-zellen.
IT8721055A0 (it) Derivati prostaglandinici, procedimenti per prepararli e composizioni farmaceutiche che licontengono.
ES2129022T3 (es) Proteina condromodulina-i.
ES2068957T3 (es) Procedimiento para la preparacion de esteres de castanospermina.
BG60657B2 (en) Human recombinant interleukin-2 muteins
IT1213033B (it) Esteri di n-alchil-nortropine eloro derivati ammonioquaternari aventi attivita'anti-broncospastica, procedimento per la loro preparazione e composizioni farmaceutiche che licontengono.